GSK's drug was cleared by the FDA for use in relapsed endometrial cancer with dMMR mutations in 2021, while Keytruda got the go-ahead for relapsed cases with MSI-H or dMMR mutations last year.

In endometrial cancer, upwards of 70% of tumours are mismatch repair proficient (MMRp)/microsatellite stable (MSS), so the new approval unlocks the lion's share of the market for GSK.

Endometrial Cancer Stages After being diagnosed with endometrial cancer, doctors will try to figure out if it has spread and, if so, how far. This process is called staging. The stage of a cancer ...